Provided By PR Newswire
Last update: Oct 29, 2024
NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry, scientific and investor conferences in November:
Read more at prnewswire.comNASDAQ:IMUX (7/21/2025, 3:48:04 PM)
0.9322
-0.03 (-2.9%)
Find more stocks in the Stock Screener